

Reprint Fulfillment

JCO published the pivotal phase 2b trial results for ReNeu; which evaluated GOMEKLI[™] (mirdametinib).

This article is open access to interested stakeholders and can be downloaded through **JCO*** [here](#).

*Access to the provided copyrighted material has been made available to you for your use only. Any subsequent copying, distribution, alteration, or use of this content may only be made subject to the individual copyright holder's terms and agreement.